Efficacy and Safety of Dostarlimab in Combination with Chemotherapy in Patients with Dmmr/msi-H Primary Advanced or Recurrent Endometrial Cancer in a Phase 3, Randomized, Placebo-Controlled Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Matthew A. Powell,David Cibula,David M. O'Malley,Ingrid Boere,Mark S. Shahin,Antonella Savarese,Dana M. Chase,Lucy Gilbert,Destin Black,Jorn Herrstedt,Sudarshan Sharma,Stefan Kommoss,Michael A. Gold, Anna M. Thijs,Kari Ring, Magnus Frodin Bolling,Joseph Buscema,Sarah E. Gill, Paul Nowicki,Nicole Nevadunsky, Michael Callahan,Lyndsay Willmott,Carolyn McCourt,Caroline Billingsley,Sharad A. Ghamande,Zangdong He, Morad Marco Balas,Shadi Stevens,Evelyn Fleming,Mansoor Raza Mirza

GYNECOLOGIC ONCOLOGY（2025）

Cited 0|Views0

Key words

Endometrial cancer,Primary advanced or recurrent endometrial cancer,Dostarlimab plus chemotherapy,Immunotherapy plus chemotherapy,dMMR/MSI-H endometrial cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined